Pharmacokinetic Studies of Single and Multiple Oral Doses of Fampridine-SR (Sustained-Release 4-Aminopyridine) in Patients With Chronic Spinal Cord Injury
Authors:
- Keith C. HayesKHKeith C. Hayes
- Patrick J. PotterPPPatrick J. Potter
- Robert R. HanseboutRHRobert R. Hansebout
- Joanne M. BugarestiJBJoanne M. Bugaresti
- Jane T. C. HsiehJHJane T. C. Hsieh
- Sera NicosiaSNSera Nicosia
- Mitchell A. KatzMKMitchell A. Katz
- Andrew R. BlightABAndrew R. Blight
- Ron CohenRCRon Cohen
- 1 July 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 26 (4) , 185-192
Abstract
Fampridine (4-aminopyridine) is a potassium channel blocking agent that restores conduction in demyelinated axons and improves neurologic function in patients with chronic spinal cord injury (SCI). Based on the pharmacokinetic profile of orally administered fampridine, multiple daily doses (4 or more) would need to be taken to sustain its therapeutic effects. Two studies were conducted to determine the pharmacokinetics and safety profile of an oral, sustained-release (SR) formulation of fampridine (fampridine-SR, 10–25 mg) administered as a single dose (n = 14) and twice daily for 1 week (n = 16) in patients with chronic, incomplete SCI. Mean plasma concentrations and area under the plasma concentration–time curve were proportional to the dose administered, whereas other pharmacokinetic parameters were independent of dose. Fampridine-SR was absorbed slowly (peak plasma concentration shortly after dosing, 2.6–3.7 hours) and eliminated (plasma half-life, 5.6–7.6 hours), and reached steady state after 4 days of twice-daily administration. Fampridine-SR was well tolerated, with only mild to moderate adverse events reported, and no serious adverse events. The extended plasma half-life of fampridine-SR allows convenient twice-daily dosing. Clinical trials designed to assess neurologic and functional improvement using fampridine-SR in patients with chronic SCI are currently underway.Keywords
This publication has 21 references indexed in Scilit:
- Absorption Characteristics of Sustained‐Release 4‐Aminopyridine (Fampridine SR) in Patients with Chronic Spinal Cord InjuryThe Journal of Clinical Pharmacology, 2000
- Randomized Double-Blind Crossover Trial of Fampridine-SR (Sustained Release 4-Aminopyridine) in Patients With Incomplete Spinal Cord InjuryJournal of Neurotrauma, 1998
- Effects of 4-Aminopyridine on Motor Evoked Potentials in Patients with Spinal Cord InjuryJournal of Neurotrauma, 1997
- 4-Aminopyridine-Sensitive Neurologic Deficits in Patients with Spinal Cord InjuryJournal of Neurotrauma, 1994
- Editorial : Aminopyridines and the Treatment of Spinal Cord InjuryJournal of Neurotrauma, 1993
- 4-Aminopyridine in Chronic Spinal Cord Injury: A Controlled, Double-Blind, Crossover Study in Eight PatientsJournal of Neurotrauma, 1993
- The effect of 4‐aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo‐controlled, double‐blind, cross‐over studyAnnals of Neurology, 1992
- Orally administered 4‐aminopyridine improves clinical signs in multiple sclerosisAnnals of Neurology, 1990
- Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injuryBrain Research Bulletin, 1989
- Physiological effects of 4‐aminopyridine on demyelinated mammalian motor and sensory fibersAnnals of Neurology, 1987